

12th August, 2025

To,

**The Corporate Relationship Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.
Scrip Code: 539523

**National Stock Exchange of India
Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.
Scrip Symbol: ALKEM

Sub: Outcome of the Board Meeting held on 12th August, 2025

Dear Sir(s)/ Madam,

This is in reference to our earlier intimation dated 04th August, 2025, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 12th August, 2025 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2025.

The Board of Directors at its meeting held today, i.e. 12th August, 2025 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2025. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.25 p.m.

The above information is also available on the website of the Company at www.alkemlabs.com

Kindly take the same on record.

Sincerely,
For Alkem Laboratories Limited



Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its associate for the quarter ended June 30, 2025 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells LLP

6. We did not review the interim financial information / financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total revenues of Rs. 3,548.2 million for the quarter ended June 30, 2025, total net profit after tax of Rs. 145.5 million for the quarter ended June 30, 2025 and total comprehensive income of Rs. 156.1 million for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information/ financial results of twenty one subsidiaries which have not been reviewed by their auditors, whose financial information/ financial results reflect total revenue of Rs. 2,156.9 million for the quarter ended June 30, 2025, total net profit after tax of Rs. 68.9 million for the quarter ended June 30, 2025 and total comprehensive income of Rs. 114.2 million for the quarter ended June 30, 2025, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. (4.1 million) for the quarter ended June 30, 2025 and total comprehensive income of Rs. (4.1 million) for the quarter ended June 30, 2025, as considered in the Statement, in respect of one associate, based on their interim financial information which have not been reviewed by their auditor. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

8. The comparative financial information of the Group for the quarter ended June 30, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed, by the predecessor auditor. The report of the predecessor auditor on this comparative financial information dated August 09, 2024 expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

 For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: **25046930BMODSM8582**)

Place: Mumbai
Date: August 12, 2025

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

S.N.	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings S.a.r.l.
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Private Limited, India	Subsidiary
11	Indchemie Health Specialties Private Limited, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation, India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
30	Alkem Wellness Limited	Wholly Owned Subsidiary
31	Adroit Biomed Limited	Wholly Owned Subsidiary
32	Bombay Ortho Industries Private Limited	Wholly Owned Subsidiary of Alkem Medtech Private Limited, India
33	Haystack Analytics Private Limited	Associate

Q

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Consolidated Financial Results for the Quarter ended 30 June 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2025 Unaudited (Refer Note 2)	31.03.2025 Unaudited (Refer Note 3)	30.06.2024 Unaudited (Refer Note 4)	31.03.2025 Audited
1	Income				
	(a) Revenue from Operations	33,711.4	31,437.5	30,318.2	129,645.2
	(b) Other Income	1,364.9	1,459.6	1,203.1	4,937.4
	Total Income	35,076.3	32,897.1	31,521.3	134,582.6
2	Expenses				
	(a) Cost of materials consumed	8,271.1	7,770.3	8,371.6	34,403.7
	(b) Purchases of stock-in-trade	3,972.0	3,799.6	3,826.6	15,140.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(531.5)	1,222.9	(1,438.7)	(1,901.3)
	(d) Employee benefits expense	6,932.5	6,163.5	6,022.7	24,539.2
	(e) Finance costs	297.8	284.2	291.1	1,217.0
	(f) Depreciation and amortisation expense	876.8	1,124.9	804.8	3,571.6
	(g) Other expenses	7,676.8	8,568.3	7,449.6	32,341.9
	Total Expenses	27,495.5	28,933.7	25,327.7	109,312.3
3	Profit before exceptional items and tax (1) - (2)	7,580.8	3,963.4	6,193.6	25,270.3
4	Exceptional items (refer note 6)	129.3	-	-	-
5	Profit before tax (3) + (4)	7,710.1	3,963.4	6,193.6	25,270.3
6	Tax expense / (credit)				
	(a) Current tax	1,411.1	842.5	1,244.3	5,236.0
	(b) Deferred tax	(384.2)	(109.2)	(553.1)	(2,125.7)
	Total Tax Expense (a + b)	1,026.9	733.3	691.2	3,110.3
7	Share in loss after tax of associate	(4.1)	(6.2)	-	(6.2)
8	Profit for the period (5) - (6) + (7)	6,679.1	3,223.9	5,502.4	22,153.8
9	Other Comprehensive Income (net of tax)				
	(a) (i) Items that will not be reclassified to profit or loss	(47.6)	(64.3)	(49.8)	(218.1)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.9	21.7	16.0	72.1
	(b) (i) Items that will be reclassified to profit or loss	65.5	16.7	74.9	343.2
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of tax)	20.8	(25.9)	41.1	197.2
10	Total Comprehensive Income for the period (8) + (9)	6,699.9	3,198.0	5,543.5	22,351.0
11	Profit attributable to				
	a) Owners of the Company	6,642.6	3,058.6	5,451.6	21,654.8
	b) Non-Controlling Interest	36.5	165.3	50.8	499.0
12	Other Comprehensive Income attributable to				
	a) Owners of the Company	23.1	(25.8)	44.1	207.5
	b) Non-Controlling Interest	(2.3)	(0.1)	(3.0)	(10.3)
13	Total Comprehensive Income attributable to				
	a) Owners of the Company	6,665.7	3,032.8	5,495.7	21,862.3
	b) Non-Controlling Interest	34.2	165.2	47.8	488.7
14	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
15	Other Equity				119,609.6
16	Earnings Per Share (not annualised for the quarters) (face value of ₹ 2/- each)				
	(a) Basic (₹)	55.56	25.57	45.60	181.11
	(b) Diluted (₹)	55.56	25.57	45.60	181.11

Notes to the Consolidated Financial results:

- 1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025.
- 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- 4 The comparative financial results of the Group for the quarter ended 30 June 2024, prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial results is dated 9 August 2024.
- 5 The Group has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025:
 - (a) 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of ₹1,400 Million subject to conditions in the agreement.
 - (b) 100% stake in Bombay Ortho Industries Private Limited, on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of ₹1,470 Million subject to conditions in the agreement.The said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025.
- 6 Exceptional items for the quarter ended 30 June 2025 primarily includes:
 - (a) Gain of ₹ 142.9 million from the sale of Indore facility classified as held for sale in the previous year and sold in the current period in accordance with the business transfer agreement entered with the buyer.
- 7 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 12 August 2025

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

5. The comparative financial information of the Company for the quarter ended June 30, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on these comparative financial information dated August 09, 2024, expressed an unmodified conclusion. These previously issued financial information have been adjusted to comply with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed by us, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.



For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: 25046930BMODSL5250)

Place: Mumbai
Date: August 12, 2025

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter ended 30 June 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited) (Refer Note 2)	31.03.2025 (Unaudited) (Refer Note 3)	30.06.2024 (Unaudited) (Refer Note 5)	31.03.2025 (Audited)
1	Continuing Operations				
	Income				
	(a) Revenue from Operations	23,721.7	20,449.4	21,269.6	88,134.4
	(b) Other Income	1,165.8	1,115.9	1,061.0	5,070.6
	Total Income	24,887.5	21,565.3	22,330.6	93,205.0
2	Expenses				
	(a) Cost of materials consumed	6,153.3	4,514.1	6,079.7	23,959.2
	(b) Purchases of stock-in-trade	835.1	852.4	783.6	3,896.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.3	1,871.4	(418.6)	566.1
	(d) Employee benefits expense	4,697.4	4,016.3	4,007.0	16,309.6
	(e) Finance costs	127.9	169.1	210.2	761.1
	(f) Depreciation and amortisation expenses	588.9	916.4	630.6	2,836.1
	(g) Other expenses	5,751.8	6,227.3	5,205.2	21,841.4
	Total Expenses	18,233.7	18,567.0	16,497.7	70,169.6
3	Profit before exceptional items and tax from continuing operations (1) - (2)	6,653.8	2,998.3	5,832.9	23,035.4
4	Exceptional items (Refer note 6)	142.9	-	-	-
5	Profit before tax from continuing operations (3) + (4)	6,796.7	2,998.3	5,832.9	23,035.4
6	Tax expense / (credit)				
	(a) Current tax	1,093.4	367.5	911.2	3,501.3
	(b) Deferred tax	(519.3)	372.0	(535.7)	(1,363.1)
	Total Tax expense (a + b)	574.1	739.5	375.5	2,138.2
7	Profit for the period after tax from continuing operations (5 - 6)	6,222.6	2,258.8	5,457.4	20,897.2
	Discontinued operations (Refer note 4)				
	Profit before tax from discontinued operations	521.0	784.8	576.5	2,938.5
	Tax expense of discontinued operations	182.0	274.2	201.4	1,026.8
8	Profit from discontinued operations (after tax)	339.0	510.6	375.1	1,911.7
9	Profit for the period (7) + (8)	6,561.6	2,769.4	5,832.5	22,808.9
10	Other Comprehensive Income (net of tax)				
	I. In respect of continuing operations:				
	(a) (i) Items that will not be reclassified to profit or loss	(31.4)	(50.8)	(36.6)	(170.3)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	11.0	17.7	12.8	59.5
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	II. In respect of discontinued operations:				
	(a) (i) Items that will not be reclassified to profit or loss	(1.7)	(11.2)	(1.6)	(6.5)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.6	4.0	0.6	2.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of tax)	(21.5)	(40.3)	(24.8)	(115.0)
11	Total Comprehensive Income for the period (9) + (10)	6,540.1	2,729.1	5,807.7	22,693.9
12	Paid-up Equity Share Capital	239.1	239.1	239.1	239.1
13	Other Equity				122,979.2
14	Earnings Per Share (not annualised for the quarters) (for continuing operations) (face value of ₹ 2/- each)				
	(a) Basic (₹)	52.04	18.89	45.64	174.78
	(b) Diluted (₹)	52.04	18.89	45.64	174.78
	Earnings Per Share (not annualised for the quarters) (for discontinued operations) (face value of ₹ 2/- each)				
	(a) Basic (₹)	2.84	4.28	3.14	15.99
	(b) Diluted (₹)	2.84	4.28	3.14	15.99
	Earnings Per Share (not annualised for the quarters) (from total operations) (face value of ₹ 2/- each)				
	(a) Basic (₹)	54.88	23.17	48.78	190.77
	(b) Diluted (₹)	54.88	23.17	48.78	190.77

Notes to the Standalone Financial results:

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025.
- 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- 4 The Board of Directors of the Company at their meeting held on 10 December 2024 have approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis.

Consequently the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous period have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

The Company is currently in process of executing the Business Transfer Agreement (BTA) which is expected to be completed on 01 October 2025.

Key financial information of Discontinued Operations:


Particulars	Quarter ended			(₹ in Million)
	30.06.2025	31.03.2025	30.06.2024	Year ended 31.03.2025
Total income	3,558.2	5,190.5	3,731.4	18,974.9
Total expenses	3,037.2	4,405.7	3,154.9	16,036.4
Profit before tax	521.0	784.8	576.5	2,938.5
Total tax expense	182.0	274.2	201.4	1,026.8
Net profit for the period	339.0	510.6	375.1	1,911.7

- 5 The comparative financial information of the Company for the quarter ended 30 June 2024, prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial information is dated 09 August 2024. These previously issued financial information have been adjusted to comply with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed by existing auditors, as applicable.
- 6 During the previous year, the Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility has been sold in the current quarter in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹ 142.9 million has been classified and disclosed as an Exceptional Item in the results for the quarter ended June 30, 2025.
- 7 The Company has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025:
 - (a) 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of ₹1,400 Million subject to conditions in the agreement.
 - (b) 100% stake in Bombay Ortho Industries Private Limited, on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of ₹1,470 Million subject to conditions in the agreement.

The said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025.

- 8 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 12 August 2025